Pharma Pricing: Trump Deals vs. Market Increases

Despite President Trump securing drug pricing agreements with 16 pharmaceutical companies including Pfizer (PFE) and Merck (MRK), every participating firm proceeded to implement price increases averaging 4% in January 2026. This gap underscores the narrow reach of these voluntary “most favored nation” arrangements, which predominantly target Medicaid programs and cash-paying consumers while leaving broader commercial markets largely unaffected.

Key Takeaways

All 16 Trump deal companies raised some drug prices
Price increases averaged 4%, matching 2025 levels despite agreements
Deals mainly impact Medicaid, TrumpRx platform, not commercial insurance

Market Reality vs. Political Theater

The pharmaceutical industry’s conventional January pricing adjustments continued unabated despite the Trump administration’s highly publicized most favored nation pricing initiative. Research firm 46brooklyn documented price increases on 872 brand-name medications during the first two weeks of 2026 ¹.

Pfizer, which became the inaugural signatory in September, implemented price increases across 72 products, notably raising its COVID vaccine cost by 15%. Similarly, Merck advanced prices on 18 products, affecting treatments like HIV medication Isentress and insomnia drug Belsomra ².

Limited Scope of Agreements

The December announcement featured nine major companies: Amgen (AMGN), Bristol Myers Squibb (BMY), Boehringer Ingelheim, Genentech, Gilead Sciences (GILD), GSK (GSK), Merck (MRK), Novartis (NVS), and Sanofi (SNY). These organizations agreed to supply medications to state Medicaid programs at internationally competitive rates and provide discounts via the TrumpRx platform set to launch in early 2026 ³.

Antonio Ciaccia, CEO of 46brooklyn, observed: “The real truth serum is what’s happening in the marketplace after those deals occur. January is prime time for list price changes on brand-name drugs. So in examining where we are today, we’re pretty much in line with the last few years” ¹.

Actual Price Movements

Although most medications experienced increases, certain significant reductions resulted from Medicare price negotiations launched under the Biden administration’s Inflation Reduction Act. Novo Nordisk implemented a 75% commercial price reduction for its insulin product Fiasp, while AstraZeneca’s Farxiga and Bristol Myers Squibb’s Eliquis experienced decreases ranging from 37% to 44% ¹.

The participating companies committed more than $150 billion toward domestic research, development, and manufacturing activities in return for three-year exemptions from proposed pharmaceutical tariffs ⁴.

Industry Response and Future Impact

White House spokesperson Kush Desai minimized the importance of list price increases, highlighting that the agreements concentrate on particular Medicaid discounts and cash-paying customers instead of commercial insurance markets. Dr. Ben Rome of Brigham and Women’s Hospital observed that “those deals probably are not very important in terms of manufacturer drug pricing and the prices paid by most Americans for prescription drugs” ¹.

The administration revealed intentions to request Congressional legislation supporting its Great Healthcare Plan, with Dr. Mehmet Oz stating it would “codify” the negotiated pharmaceutical company agreements ¹.

Market Outlook

Continued price escalations despite prominent political commitments indicate that substantial pharmaceutical cost reduction demands more thorough regulatory intervention than voluntary corporate pledges. Medicare’s direct price negotiation demonstrates greater effectiveness in achieving tangible reductions, as shown by the 38% to 79% decreases for 10 medications in the program’s initial phase ¹.

Investors should track whether these agreements’ restricted scope influences companies’ capacity to sustain pricing power in their primary commercial markets, where the majority of revenue originates.

Not investment advice. For informational purposes only.